(Q82829017)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hajime Asahina

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Noboru Yamamoto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hiroshi Nokihara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Yasuhide Yamada

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Yasushi Goto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Takashi Shibata

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kazuhiko Yamada

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Toshio Kawata

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Xiaojin Shi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Tomohide Tamura

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

30 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

504-509

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

18 January 2020

cites work

1 reference

12 December 2020

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

12 December 2020

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

1 reference

12 December 2020

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

12 December 2020

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

1 reference

12 December 2020

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

12 December 2020

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Efficient Deletion of NormalBrca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy

1 reference

12 December 2020

10.1111/J.1349-7006.2011.02179.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145984%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference